Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 11:04:32 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Canada beats Czechs 4
Next:Election deniers moving closer to GOP mainstream as Trump allies fill Congress, report shows
You may also like
- Testimony at Sen. Bob Menendez's bribery trial focuses on his wife's New Jersey home
- World's highest UHV transmission tower completes construction
- China's new factory data evidence of good momentum in its economy: FM spokesperson
- Protests erupt as concerns rise in ROK, Philippines
- Guardians ruin Francisco Lindor's Cleveland homecoming, trip Mets 3
- 3 killed in military helicopter crash in Cuba
- Insights丨 Literature works bridge for communications between China and Brazil: Brazilian professor
- World's highest UHV transmission tower completes construction
- Election 2024: Biden and the Democrats raised far less in April than Trump and the GOP